Biogen Receives Complete Response Letter from FDA for High Dose Nusinersen in Spinal Muscular Atrophy

Biogen announced that the FDA issued a Complete Response Letter (CRL) for its supplemental New Drug Application (sNDA) for a high dose regimen of nusi...